Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Peripheral Arterial Disease Pad Pulmonary Vascular Disease Pvd Pipeline Insight

DelveInsight’s, “Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) – Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Understanding

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Overview

Peripheral artery disease (PAD) refers to diseases of the blood vessels located outside the heart and brain. PAD is a chronic disease in which plaque builds up in the arteries of the legs. It is more common in people who are 65 or older, but can occur at nearly any age. Smoking; high blood pressure; high cholesterol or triglycerides; diabetes; kidney failure; and obesity increase risk for PAD. While many people with peripheral artery disease have mild or no symptoms, some people have leg pain when walking. Possible symptoms include: Hair loss on the feet and legs, Numbness in the legs, A foot or the lower leg may feel cold, and leg weakness. Symptoms and medical history are being questioned by the doctor for the appropriate diagnossi of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD). PAD is usually treated by aggressively managing the risk factors with lifestyle changes and medication. This includes quitting smoking, controlling blood pressure and cholesterol, controlling diabetes, and losing weight. Surgery, medications and angioplasty are some other treatment options for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD).


"Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) pipeline landscape is provided which includes the disease overview and Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) treatment guidelines. The assessment part of the report embraces, in depth Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD).

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Emerging Drugs Chapters

This segment of the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Emerging Drugs


Rivaroxaban: Janssen Pharmaceutical

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). A supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto; Janssen) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD) has been submitted to the Food and Drug Administration (FDA).


Semaglutide: Novo Nordisk

Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently in Phase III stage of development for the treatment of patients with Type 2Diabetes Mellitus, and Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD).

Further product details are provided in the report……..

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Therapeutic Assessment

This segment of the report provides insights about the different Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

There are approx. 20+ key companies which are developing the therapies for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD). The companies which have their Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) drug candidates in the most advanced stage, i.e. Preregistration include, Janssen Pharmaceutical.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) drugs.

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Report Insights

  • Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) drugs?
  • How many Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD): Overview

  • Causes
  • Mechanism of Action 
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type 

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration) 

  • Comparative Analysis

Rivaroxaban: Janssen Pharmaceutical

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Mid Stage Products (Phase II) 

  • Comparative Analysis

JVS-100: Juventas Therapeutics

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Early stage products (Phase I)

  • Comparative Analysis

FGF-1:Venturis Therapeutics

  • Product Description
  • Research and Development 
  • Product Development Activities 

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Key Companies

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Key Products

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)- Unmet Needs

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)- Market Drivers and Barriers

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)- Future Perspectives and Conclusion

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Analyst Views

Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD) Key Companies

Appendix

List of Table

Table 1: Total Products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Peripheral Arterial Disease (PAD)/ Pulmonary Vascular Disease (PVD)

Figure 2: Late Stage Products

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Bayer/Johnson & Johnson Pharmaceutical

• Novo Nordisk

• SK chemicals

• Takeda

• Mercator MedSystems

• Helixmith Co., Ltd.

• Beijing Northland Biotech. Co., Ltd.

• Juventas Therapeutics

• CSPC ZhongQi Pharmaceutical Technology

• AnGes USA, Inc.

• Aldagen

• CardioVascular BioTherapeutics Inc

• BioGenCell

• Alucent Biomedical

• Symic Bio

• AngioSoma

• JanOne

Forward to Friend

Need A Quote